Developer docs
API playgroundTry for free, no card

Search company profiles

Deciduous Therapeutics

Full company profile

uuid0002364

Namestring
Deciduous Therapeutics
Legal namestring
Deciduous Therapeutics Inc.
Websiteurl
deciduoustx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Deciduous Therapeutics is an early-stage, venture-backed biotechnology company headquartered at 953 Indiana Street in San Francisco, California. The company is developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells — via lipid antigen presentation — to selectively eliminate senescent cells, which accumulate with age and drive inflammation, extracellular matrix remodeling, and progression of age-related diseases. The foundational scientific discovery was published in the peer-reviewed journal Med (Cell Press) in 2021, and the company has demonstrated in vivo proof-of-concept in both fibrotic and metabolic disease models, achieving therapeutically relevant endpoints and durable effects in preclinical studies. Initial pipeline focus is on age-related fibrotic and metabolic diseases, with explicit plans to expand into additional indications through multiple activation approaches.

The company is led by Co-founder and CEO Robin Mansukhani (formerly co-founder and President & CEO of Alzeca Biosciences) and Scientific Founder Dr. Anil Bhushan, with VP of Research Dr. Vladi Juric (postdoctoral training under Nobel Laureate J. Michael Bishop, ex-Gilead, ex-Pionyr Immunotherapeutics) overseeing R&D. The team includes roughly 11–50 employees spanning clinical development, toxicology, medicinal chemistry, and immunology, supported by a Scientific Advisory Board that includes Dr. Max Krummel and Dr. Eric Verdin, an independent board member Robert Forrester, and high-profile investor Thomas Ebeling (former CEO of Novartis). The company has secured two incubator Golden Ticket awards (Bakar Labs at UC Berkeley in October 2021 and Eisai Innovation/MBC BioLabs in November 2021), along with approximately $16.5 million in disclosed venture funding from investors including CRV, 8VC, Presight Capital, The Longevity Fund, Global Brain Corporation, Bold Capital Partners, Healthspan Capital, Humboldt Fund, and Owl Capital.

Deciduous Therapeutics is pre-revenue and does not yet have commercial products or established pricing. The business model is structured around traditional pharmaceutical development: venture-backed R&D funding flows into preclinical research, with anticipated future revenue from pharmaceutical product sales and/or licensing upon successful clinical development and regulatory approval. Marketing and GTM efforts to date have been concentrated on top-of-funnel scientific outreach, including peer-reviewed publication in Med, conference presentations (Longevity Leaders World Congress), earned media in outlets such as STAT News and Endpoints News, podcast appearances, and partnerships with advocacy organizations such as the Alliance for Longevity Initiatives. The eventual commercial GTM motion is expected to follow enterprise field sales patterns through traditional pharmaceutical distribution channels, contingent on successful clinical translation.

Short descriptiontext

Deciduous Therapeutics is a venture-backed, pre-revenue biotech developing immunotherapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells, targeting age-related fibrotic and metabolic diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
senolytic immunotherapy, cellular senescence drugs, age-related disease therapeutics, iNKT cell activation, fibrotic disease treatment
Industry2 codes
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Senolytic Immunotherapy
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Novel Medicines Development
TypeOne Time License
Description

Pre-revenue biotech company developing novel immunotherapies for age-related diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

deciduoustx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Deciduous Therapeutics is a pre-revenue biotech developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic conditions, leveraging lipid antigen presentation as an endogenous immune surveillance mechanism for senolytic therapy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Demonstrated senescent cell clearance in disease models through NKT cell activation
+1 more record
Product overview1 text field

Deciduous Therapeutics is developing novel immunotherapies that activate endogenous immune mechanisms to selectively eliminate senescent cells. Their therapeutic approach focuses on activating invariant natural killer T (iNKT) cells to clear pathogenic senescent cells, offering a differentiated mechanism compared to traditional senolytic drugs. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic diseases. As an early-stage biotech company, they are translating discoveries from their scientific founder's lab toward clinical applications.

Product and service1 record
1NKT Cell-Activating Senolytic Immunotherapy Pipeline
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-11-01
Description

Deciduous Therapeutics won the inaugural Eisai Innovation, Inc. and MBC BioLabs Golden Ticket Competition in 2021. The competition provides winning companies with lab space in MBC BioLabs facility in San Francisco to pursue drug discovery and innovation for potential future benefit of patients. MBC BioLabs provides state-of-the-art laboratory facilities and an ecosystem supporting biotech startups.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-10-21
Description

Deciduous Therapeutics won a 2021 Golden Ticket from Bakar Labs, the flagship life science incubator at UC Berkeley's Bakar BioEnginuity Hub. The Golden Ticket grants access to free lab space and facilities for one year, providing a substantial head start in commercializing technologies. Bakar Labs offers more than 20,000 square feet of premium experimental space and access to campus resources, industry partners, and a community of up to 50 fellow resident startups. The program is sponsored by AbbVie as an inaugural member of Bakar Labs Incubator.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Deciduous Therapeutics CEO Robin Mansukhani participated in the A4LI virtual conference on longevity science, joining other longevity scientists, biotech executives, and investors to discuss advances in aging biology, therapeutic development, and healthspan extension.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage immuno-oncology company developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases. Most direct peer given the shared iNKT-cell therapeutic axis; Deciduous even has team alumni (Darrian Moskowitz) from MiNK's allogeneic iNKT program.

TypeDirect peer
Description

Clinical-stage senolytic drug developer (UBX0101, UBX1325) targeting senescent cells for age-related ophthalmologic and musculoskeletal diseases. Direct therapeutic-target peer for senescent-cell clearance in age-related disease, although via small-molecule rather than immune-mediated mechanism.

TypeDirect peer
Description

Privately held senolytic company developing plasmid-DNA-based gene therapy to selectively eliminate senescent cells. Pursues the same senescent-cell-clearance therapeutic hypothesis as Deciduous but via a fundamentally different (gene-therapy) modality.

TypeDirect peer
Description

Early-stage senolytic startup developing small-molecule FOXO4-DRI peptide therapeutics to selectively clear senescent cells. Direct therapeutic-target competitor in the same senolytic space as Deciduous.

TypeEmerging player
Description

Clinical-stage biotech developing integrin-targeting therapies for fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Overlaps with Deciduous's initial fibrotic-disease indication focus and shares Dr. Greg Cosgrove (former VP Clinical Development at Pliant) on the team.

TypeEmerging player
Description

Clinical-stage aging therapeutics company developing small-molecule drugs that target pathways driving age-related disease. Comparable aging-therapeutics stage and target patient population, and Deciduous CEO appeared on BioAge's 'Translating Aging' podcast — direct ecosystem overlap.

7Pionyr Immunotherapeutics
TypeEmerging player
Description

Immuno-oncology company developing myeloid-targeting antibodies (acquired by Gilead in 2023). Strong ecosystem overlap: Deciduous VP Research Dr. Vladi Juric previously led myeloid-reprogramming antibody programs at Pionyr toward the clinic.

TypeBroad incumbent
Description

Well-capitalized ($3B+ raised) cell-reprogramming and aging-biology company pursuing cellular rejuvenation therapies. Operates in the same longevity/age-related-disease thesis at vastly greater scale and capital depth; represents the bull-case ceiling for the aging-therapeutics market.

TypeBroad incumbent
Description

Alphabet-backed longevity R&D organization pursuing fundamental research into the biology of aging and age-related disease. Larger, broader portfolio player in the same aging-therapeutics thesis with deep pharma-style resources.

TypeBroad incumbent
Description

AI-driven drug-discovery company advancing aging and age-related-disease programs (including IPF and T2D candidates) into the clinic. Operates in the same age-related-disease pipeline space with significantly larger resources and broader pipeline.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Deciduous Therapeutics

Senolytic Immunotherapydeciduoustx.com

Deciduous Therapeutics is a venture-backed, pre-revenue biotech developing immunotherapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells, targeting age-related fibrotic and metabolic diseases.

What Deciduous Therapeutics does

Deciduous Therapeutics is an early-stage, venture-backed biotechnology company headquartered at 953 Indiana Street in San Francisco, California. The company is developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells — via lipid antigen presentation — to selectively eliminate senescent cells, which accumulate with age and drive inflammation, extracellular matrix remodeling, and progression of age-related diseases. The foundational scientific discovery was published in the peer-reviewed journal Med (Cell Press) in 2021, and the company has demonstrated in vivo proof-of-concept in both fibrotic and metabolic disease models, achieving therapeutically relevant endpoints and durable effects in preclinical studies. Initial pipeline focus is on age-related fibrotic and metabolic diseases, with explicit plans to expand into additional indications through multiple activation approaches.

The company is led by Co-founder and CEO Robin Mansukhani (formerly co-founder and President & CEO of Alzeca Biosciences) and Scientific Founder Dr. Anil Bhushan, with VP of Research Dr. Vladi Juric (postdoctoral training under Nobel Laureate J. Michael Bishop, ex-Gilead, ex-Pionyr Immunotherapeutics) overseeing R&D. The team includes roughly 11–50 employees spanning clinical development, toxicology, medicinal chemistry, and immunology, supported by a Scientific Advisory Board that includes Dr. Max Krummel and Dr. Eric Verdin, an independent board member Robert Forrester, and high-profile investor Thomas Ebeling (former CEO of Novartis). The company has secured two incubator Golden Ticket awards (Bakar Labs at UC Berkeley in October 2021 and Eisai Innovation/MBC BioLabs in November 2021), along with approximately $16.5 million in disclosed venture funding from investors including CRV, 8VC, Presight Capital, The Longevity Fund, Global Brain Corporation, Bold Capital Partners, Healthspan Capital, Humboldt Fund, and Owl Capital.

Deciduous Therapeutics is pre-revenue and does not yet have commercial products or established pricing. The business model is structured around traditional pharmaceutical development: venture-backed R&D funding flows into preclinical research, with anticipated future revenue from pharmaceutical product sales and/or licensing upon successful clinical development and regulatory approval. Marketing and GTM efforts to date have been concentrated on top-of-funnel scientific outreach, including peer-reviewed publication in Med, conference presentations (Longevity Leaders World Congress), earned media in outlets such as STAT News and Endpoints News, podcast appearances, and partnerships with advocacy organizations such as the Alliance for Longevity Initiatives. The eventual commercial GTM motion is expected to follow enterprise field sales patterns through traditional pharmaceutical distribution channels, contingent on successful clinical translation.

Deciduous Therapeutics firmographics

Firmographics
Name
Deciduous Therapeutics
Legal name
Deciduous Therapeutics Inc.
Website
https://deciduoustx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Deciduous Therapeutics is a venture-backed, pre-revenue biotech developing immunotherapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells, targeting age-related fibrotic and metabolic diseases.
Ownership category
akta.pro rank

Deciduous Therapeutics industry classification

Industry
Product category
Senolytic Immunotherapy
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAGAL
Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAABAB
Cell Therapy Developers (Allogeneic/Off-the-shelf)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Senolytic immunotherapy
  • Cellular senescence drugs
  • Age-related disease therapeutics
  • INKT cell activation
  • Fibrotic disease treatment

Where Deciduous Therapeutics is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Deciduous Therapeutics business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Revenue model

  1. Novel Medicines Development: Pre-revenue biotech company developing novel immunotherapies for age-related diseases. Revenue will be generated through pharmaceutical product sales upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Deciduous Therapeutics product offering

Product offering

Core offering

Deciduous Therapeutics is a pre-revenue biotech developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic conditions, leveraging lipid antigen presentation as an endogenous immune surveillance mechanism for senolytic therapy.

Product overview

Deciduous Therapeutics is developing novel immunotherapies that activate endogenous immune mechanisms to selectively eliminate senescent cells. Their therapeutic approach focuses on activating invariant natural killer T (iNKT) cells to clear pathogenic senescent cells, offering a differentiated mechanism compared to traditional senolytic drugs. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic diseases. As an early-stage biotech company, they are translating discoveries from their scientific founder's lab toward clinical applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • NKT Cell-Activating Senolytic Immunotherapy Pipeline

Quantifiable outcome

  • Demonstrated senescent cell clearance in disease models through NKT cell activation
  • +1 more outcomes

Companies that use Deciduous Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Deciduous Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Deciduous Therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and minor.

  • MBC BioLabs / Eisai InnovationcoreStrategic or Co-development Partner · 1 November 2021Deciduous Therapeutics won the inaugural Eisai Innovation, Inc. and MBC BioLabs Golden Ticket Competition in 2021. The competition provides winning companies with lab space in MBC BioLabs facility in San Francisco to pursue drug discovery and innovation for potential future benefit of patients. MBC BioLabs provides state-of-the-art laboratory facilities and an ecosystem supporting biotech startups.
  • Bakar LabscoreStrategic or Co-development Partner · 21 October 2021Deciduous Therapeutics won a 2021 Golden Ticket from Bakar Labs, the flagship life science incubator at UC Berkeley's Bakar BioEnginuity Hub. The Golden Ticket grants access to free lab space and facilities for one year, providing a substantial head start in commercializing technologies. Bakar Labs offers more than 20,000 square feet of premium experimental space and access to campus resources, industry partners, and a community of up to 50 fellow resident startups. The program is sponsored by AbbVie as an inaugural member of Bakar Labs Incubator.
  • Alliance for Longevity Initiatives (A4LI)minorGTM or Marketing PartnerDeciduous Therapeutics CEO Robin Mansukhani participated in the A4LI virtual conference on longevity science, joining other longevity scientists, biotech executives, and investors to discuss advances in aging biology, therapeutic development, and healthspan extension.

Scale indicators2 records

Recent moves8 records

Expansion highlights5 records

Deciduous Therapeutics competitors and assessment

Company assessment

Direct peers

  • MiNK Therapeutics: Clinical-stage immuno-oncology company developing allogeneic iNKT cell therapies for cancer and immune-mediated diseases. Most direct peer given the shared iNKT-cell therapeutic axis; Deciduous even has team alumni (Darrian Moskowitz) from MiNK's allogeneic iNKT program.
  • Unity Biotechnology: Clinical-stage senolytic drug developer (UBX0101, UBX1325) targeting senescent cells for age-related ophthalmologic and musculoskeletal diseases. Direct therapeutic-target peer for senescent-cell clearance in age-related disease, although via small-molecule rather than immune-mediated mechanism.
  • Oisín Biotechnologies: Privately held senolytic company developing plasmid-DNA-based gene therapy to selectively eliminate senescent cells. Pursues the same senescent-cell-clearance therapeutic hypothesis as Deciduous but via a fundamentally different (gene-therapy) modality.
  • Cleara Biotech: Early-stage senolytic startup developing small-molecule FOXO4-DRI peptide therapeutics to selectively clear senescent cells. Direct therapeutic-target competitor in the same senolytic space as Deciduous.

Emerging players

  • Pliant Therapeutics: Clinical-stage biotech developing integrin-targeting therapies for fibrotic diseases including idiopathic pulmonary fibrosis (IPF). Overlaps with Deciduous's initial fibrotic-disease indication focus and shares Dr. Greg Cosgrove (former VP Clinical Development at Pliant) on the team.
  • BioAge Labs: Clinical-stage aging therapeutics company developing small-molecule drugs that target pathways driving age-related disease. Comparable aging-therapeutics stage and target patient population, and Deciduous CEO appeared on BioAge's 'Translating Aging' podcast — direct ecosystem overlap.
  • Pionyr Immunotherapeutics: Immuno-oncology company developing myeloid-targeting antibodies (acquired by Gilead in 2023). Strong ecosystem overlap: Deciduous VP Research Dr. Vladi Juric previously led myeloid-reprogramming antibody programs at Pionyr toward the clinic.

Broad incumbents

  • Altos Labs: Well-capitalized ($3B+ raised) cell-reprogramming and aging-biology company pursuing cellular rejuvenation therapies. Operates in the same longevity/age-related-disease thesis at vastly greater scale and capital depth; represents the bull-case ceiling for the aging-therapeutics market.
  • Calico Labs: Alphabet-backed longevity R&D organization pursuing fundamental research into the biology of aging and age-related disease. Larger, broader portfolio player in the same aging-therapeutics thesis with deep pharma-style resources.
  • Insilico Medicine: AI-driven drug-discovery company advancing aging and age-related-disease programs (including IPF and T2D candidates) into the clinic. Operates in the same age-related-disease pipeline space with significantly larger resources and broader pipeline.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Deciduous Therapeutics social profiles

Digital presence

Deciduous Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Deciduous Therapeutics leadership team

Management profile

Number of profiles

Profiles15 records

Deciduous Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Deciduous Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Deciduous Therapeutics

What does Deciduous Therapeutics do?

Deciduous Therapeutics is a pre-revenue biotech developing a novel class of immune modulatory therapies that activate invariant natural killer T (iNKT) cells to selectively eliminate senescent cells. The company's pipeline targets multiple age-related diseases including fibrotic and metabolic conditions, leveraging lipid antigen presentation as an endogenous immune surveillance mechanism for senolytic therapy.

Is Deciduous Therapeutics a public or private company?

Deciduous Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Deciduous Therapeutics founded?

Deciduous Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Deciduous Therapeutics based?

Deciduous Therapeutics is headquartered in San Francisco, United States, in the North America region.

How does Deciduous Therapeutics make money?

One revenue line is on record: novel Medicines Development.

Who are Deciduous Therapeutics's main competitors?

Direct peers on record are MiNK Therapeutics, Unity Biotechnology, Oisín Biotechnologies and Cleara Biotech. Emerging players are Pliant Therapeutics, BioAge Labs and Pionyr Immunotherapeutics. Broad incumbents are Altos Labs, Calico Labs and Insilico Medicine.

Does Deciduous Therapeutics have an API?

No public API is recorded for Deciduous Therapeutics.

What industry is Deciduous Therapeutics in?

Deciduous Therapeutics's product category is Senolytic Immunotherapy. Its primary akta.pro industry code is HLAAAGAL, Regenerative Immunology & Inflammation Modulation (pro-regenerative biologics), with a secondary code of HLAAABAB, Cell Therapy Developers (Allogeneic/Off-the-shelf). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NatureRestoring immune surveillance to tackle age-related diseasesDeciduous Therapeutics is developing a novel class of immuno-therapies aimed at treating age-related diseases by eliminating senescent cells through immune-mediated clearance. The company's approach has shown promise in mouse models, demonstrating significant improvements in conditions like metabolic and fibrotic diseases with a favorable safety profile. Their long-term vision includes making this immune therapy accessible for treating age-related health issues globally.PR NewswireLifeSpan Vision Ventures Invests in Deciduous TherapeuticsLifeSpan Vision Ventures announced an investment in Deciduous Therapeutics, a San Francisco-based longevity biotechnology company focused on eliminating senescent cells through restoring Natural Killer T-cell (NKT) immune mechanisms. The company's in vivo proof-of-concept studies demonstrated single-dose efficacy with their lead compound, which eliminates senescent cells and resolves fibrotic and metabolic diseases. Deciduous Therapeutics originated from research at the University of California, San Francisco, and the investment aligns with LifeSpan Vision Ventures' mission to support longevity and age-related disease therapeutics.The DailyA Shared Passion for Healthy Longevity Inspired this Alumni Venture Fund InvestmentDeciduous Therapeutics secured investment from the Case Western Reserve University Alumni Venture Fund, a mechanism managed by the Veale Institute for Entrepreneurship. The startup, led by CEO Robin Mansukhani, is developing immunotherapies to treat age-related diseases and had previously raised $17 million in seed funding. Student fellow Ammar Kazi led the due diligence process for the university fund, which approved the investment based on the company's novel approach to reactivating killer T cells.PR NewswireDeciduous Therapeutics Announces Appointments to the Board, SAB, and Advisor RolesDeciduous Therapeutics, an early-stage venture-backed biotech company based in San Francisco, announced board and advisory appointments including Robert Forrester as Independent Board Member, and Dr. Max Krummel and Dr. Eric Verdin as new Scientific Advisory Board members. The company is developing immunotherapies to clear senescent cells for treating age-related diseases, with its underlying discovery of immune-mediated senolysis recently published in the journal Med. These appointments bring experienced life science executives and researchers to guide the company's growth toward clinical translation.